Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vivo |
Yonkenafil (4–32 mg/kg, intravenously administered daily for seven days) has been shown to improve post-stroke behavioral outcomes, decrease the amount of cerebral infarct, prevent neuronal death, and markedly increase the expression deficits of NGF/TrkA and BDNF/TrkB. Blood brain synaptic function[1].
|
---|---|
Animal Protocol |
Animal/Disease Models: Male SD (Sprague-Dawley) Rat[1]
Doses: 4, 8, 16 and 32 mg/kg Route of Administration: iv daily for 7 days Experimental Results: Induced a dose-dependent decrease in infarct volume, with an ED50 of 12.27 mg/kg. Increased hsp70 expression, diminished apaf-1 expression, and inhibited caspase-3 and caspase-9 cleavage. Dramatically prevented neuronal damage and increases the number of surviving neurons after stroke. Prevented decrease in synaptophysin levels and increase in PSD-95 and nNOS levels. |
References |
[1]. Xuemei Chen, et al. Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke. Exp Neurol. 2014 Nov;261:267-77.
|
Molecular Formula |
C24H33N5O4S
|
---|---|
Molecular Weight |
487.61
|
CAS # |
804518-63-6
|
Related CAS # |
Yonkenafil hydrochloride;804519-64-0;Yonkenafil-d8;Yonkenafil-d7
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
C1(C2=CC(S(N3CCN(CC)CC3)(=O)=O)=CC=C2OCC)NC(=O)C2C(C)=CN(CCC)C=2N=1
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: 100 mg/mL (205.08 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.13 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.13 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.0508 mL | 10.2541 mL | 20.5082 mL | |
5 mM | 0.4102 mL | 2.0508 mL | 4.1016 mL | |
10 mM | 0.2051 mL | 1.0254 mL | 2.0508 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.